Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2021
Italy, EU refuse AstraZeneca request to ship 250,000 doses of vaccine to Australia
5 March 2021 - Italy and the European Union have blocked a shipment of the Oxford-AstraZeneca coronavirus vaccine destined for Australia ...
Posted by Michael Wonder on 28 Feb 2021
Eczema medicine Dupixent added to Pharmaceutical Benefits Scheme
26 February 2021 - Eczema has a significant effect on sufferers’ physical and mental wellbeing, but the new listing of a ...
Posted by Michael Wonder on 28 Feb 2021
New Zealand Pharmaceutical Schedule - 1 March 2021
1 March 2021 - The March 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Feb 2021
GSK receives CHMP positive opinion recommending approval of dostarlimab for women with recurrent or advanced endometrial cancer
26 February 2021 - GlaxoSmithKline today announced the CHMP of the EMA has adopted a positive opinion recommending dostarlimab, an anti-programmed ...
Posted by Michael Wonder on 27 Feb 2021
FDA issues emergency use authorisation for third COVID-19 vaccine
27 February 2021 - Action advances fight against COVID-19, follows comprehensive evaluation of available safety, effectiveness and manufacturing quality information by ...
Posted by Michael Wonder on 27 Feb 2021
FDA approves first treatment for molybdenum cofactor deficiency type A
26 February 2021 - Today, the U.S. FDA approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to ...
Posted by Michael Wonder on 26 Feb 2021
Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy treatment with proven efficacy in adults, children and infants two months and older
26 February 2021 - Evrysdi is approved in seven countries, submitted in 30 more. ...
Posted by Michael Wonder on 26 Feb 2021
FDA authorises marketing of novel device to help protect athletes’ brains during head impacts
26 February 2021 - Today, the U.S. FDA authorised marketing of a new device intended to be worn around the neck ...
Posted by Michael Wonder on 26 Feb 2021
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...
Posted by Michael Wonder on 26 Feb 2021
Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache
25 February 2021 - The first and only anti-CGRP treatment with dual indications. ...
Posted by Michael Wonder on 26 Feb 2021
BioCryst receives positive CHMP opinion for Orladeyo (berotralstat), an oral, once daily therapy to prevent attacks in patients with hereditary angioedema
25 February 2021 - BioCryst Pharmaceuticals today announced that the CHMP of the EMA has adopted a positive opinion recommending ...
Posted by Michael Wonder on 26 Feb 2021
Medexus announces expanded availability of Gleolan in Canada
25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...
Posted by Michael Wonder on 26 Feb 2021
Empirical Spine initiates PMA submission process for FDA approval of Limiflex for degenerative spondylolisthesis
25 February 2021 - The LimiFlex Paraspinous Tension Band is a new, investigational device designed as an alternative to spinal fusion ...
Posted by Michael Wonder on 26 Feb 2021
Retrotope granted rare paediatric disease designation from FDA for lead development candidate, RT001, in two life-threatening neurodegenerative indications
25 February 2021 - RT001 also granted fast track designation by FDA in Friedreich’s ataxia. ...
Posted by Michael Wonder on 25 Feb 2021
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...
Posted by Michael Wonder on 25 Feb 2021
Allergan submits new drug application for investigational AGN-190584 for the treatment of presbyopia
25 February 2021 - If approved, this is expected to be the first eye drop to treat presbyopia. ...